Terbifin

Quick links to important sections

Terbifin

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbifin

Property Description
Active ingredient Terbinafine Hydrochloride
Forms Tablet, Cream, Gel, Topical Solution, Spray
Pharmacological Class Allylamine Antifungal Agent
Origin Synthetic Compound (Allylamine derivative)

Defining Terbifin: Type and Core Composition

Terbifin is an antimycotic medication whose primary component is the active ingredient Terbinafine Hydrochloride, a synthetic compound derived from the allylamine derivative family. This agent belongs to the specialized Allylamine Antifungal pharmacological class. The structural and chemical identity of Terbinafine Hydrochloride is clinically recognized for its efficacy against a range of fungal pathogens.

Available Forms and Therapeutic Classification

Terbinafine is strategically manufactured in multiple dosage forms to suit different treatment needs. It is available as the tablet and granules for systemic use, necessary when treating deep-seated infections such as those in the nail, and as cream, gel, topical solution, or spray preparations for local application. The availability of both oral and topical routes of administration allows the medication to be categorized based on whether it is absorbed into the bloodstream (systemic use) or applied directly to the surface infection (local use).

General Purpose: Why Allylamine Antifungals are Used

The general purpose of this medication is to achieve the elimination of persistent fungal infections through a highly targeted mechanism that results in a decisive fungicidal action. This fungicidal action is achieved by disrupting the fungal cell’s ability to maintain its structure. The mechanism of Terbinafine involves the inhibition of squalene epoxidase, which confirms the specific physiological action that distinguishes the drug within the antifungal category. This activity leads to the efficient clearance of conditions like dermatomycoses, providing a necessary benefit where fungal elimination is required.

Regulatory References

  1. Terbinafine Mechanism of Action

What side effects are possible with Terbifin?

Possible Side Effects and Safety Information

The safety characteristics of Terbifin (Terbinafine Hydrochloride) are formally documented by regulatory authorities, classifying possible adverse reactions by frequency and physiological system. This classification encompasses effects across multiple System-Organ Classes, including Hepatobiliary, Nervous System, Gastrointestinal, and Blood and Lymphatic System Disorders.

Adverse reactions listed as Very Common (ge 1/10) in regulatory documents include headache, various gastrointestinal disturbances (such as diarrhea, nausea, dyspepsia, and abdominal pain), rash, urticaria, and musculoskeletal symptoms like arthralgia and myalgia. Reactions classified as Common (ge 1/100) typically involve the elevation of liver enzyme values.

Regulatory documentation highlights the potential for rare but clinically significant serious adverse reactions. These include severe Hepatobiliary Disorders, specifically acute hepatic failure, which in rare instances has resulted in death or required liver transplantation. Other serious risks documented are severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome, and severe Blood and Lymphatic System Disorders, including neutropenia and agranulocytosis.

Population-specific constraints are defined in the official prescribing information. Terbifin is formally contraindicated in individuals with a known history of hypersensitivity to the active substance and in patients with pre-existing chronic or active liver disease. Use is also generally not recommended in individuals with severely impaired renal function (Creatinine Clearance < 50 mL/min). The label notes that taste disturbance, though uncommon, may be prolonged following the cessation of systemic treatment.

Overdose and Emergency Response

The official regulatory documentation for Terbifin overdose describes the expected clinical manifestations following exposure to supratherapeutic doses. The most commonly documented presentations involve the gastrointestinal system, including nausea, vomiting, stomach pain, and diarrhea. Central nervous system effects are also formally cited, which include dizziness and headache. Other documented effects noted in the regulatory labels are rash and frequent urination.

Government authorities establish clear thresholds for seeking medical assistance. If an overdose is suspected, contacting the poison control helpline is mandated. Immediate contact with emergency services is required if severe or life-threatening outcomes occur, specifically if the individual experiences collapse, a seizure, trouble breathing, or becomes unresponsive (unable to be awakened).

Regulatory summaries state that no specific antidote is known for Terbifin overdose. Therefore, management is focused on providing symptomatic supportive therapy where clinically necessary. Officially described procedural steps include measures to eliminate the drug, typically through the administration of activated charcoal. This approach reflects the standardized management defined within official prescribing information.

Therapeutic Uses of Terbifin

What Terbifin Treats: Main Uses and Benefits

Terbifin is a medication that plays a role in managing conditions characterized by periods of heightened symptoms related to inflammatory or irritative states. It is commonly used across domains where additional symptomatic support is needed, and is used within therapeutic areas involving heightened responses.


Therapeutic Scope and Symptom Relief

This medication is relevant for easing symptoms that interfere with daily comfort in conditions such as onychomycosis (fungal nail infection), Tinea capitis (scalp fungus), Tinea corporis (body ringworm), and Tinea pedis (athlete's foot). It helps address symptom clusters that may become intense or disruptive, including severe nail thickening, skin scaling, and intense pruritus (itching). The use of this medication supports the management of the fungal presence, which assists with easing the impact of symptoms on routine activities.

Contextual Note: Support for Nail Appearance The medication assists with managing the appearance of nails affected by fungal infections, contributing to the gradual support for nail appearance.


Clinical Context and Patient Benefit

Terbifin is generally used across domains where short-term symptom management is appropriate for conditions that present with significant symptomatic burden, such as recurrent or severe Tinea infections, or when local management options have not achieved the desired response. Applied during phases when symptoms become more noticeable, it contributes to improved comfort by managing the symptoms of the infection and assisting with the maintenance of functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Absolute Prohibitions (Contraindications)

Oral Terbifin (Terbinafine Hydrochloride) is contraindicated and must not be used in patients diagnosed with chronic or active liver disease. The medicine is also strictly prohibited for individuals with a history of allergic reaction or hypersensitivity to oral terbinafine.


Restricted and Not Recommended Use

Use is not recommended for patients with significant renal impairment (creatinine clearance less than 50 mL/min), as established safety data are insufficient for this group. The medicine should not be used during pregnancy or by mothers who are breastfeeding, as terbinafine is excreted in breast milk. Treatment requires caution in patients with pre-existing conditions such as lupus erythematosus or psoriasis, and discontinuation is warranted if signs of lupus develop.


Age-Related Eligibility

The safety and efficacy of the oral formulation have not been established in children younger than four years of age. For geriatric patients (65 years and older), while standard dosing is generally applicable, the possibility of underlying hepatic or renal function impairment should be considered before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Terbifin (Terbinafine Hydrochloride) is primarily defined by its effects on drug metabolism. Terbifin is documented as a strong inhibitor of the CYP2D6 isozyme, a classification that affects the pharmacokinetics of numerous co-administered medicinal products that rely on this enzyme for clearance.

Official Interaction Statements

Co-administration with other medicines may result in increased or decreased systemic exposure of either Terbifin or the co-administered drug, as noted in regulatory labeling:

  • CYP2D6 Substrates: Terbifin's inhibition of this enzyme can significantly increase the exposure of substrates such as desipramine and dextromethorphan.
  • CYP Inhibitors: Strong inhibitors of enzymes like CYP2C9 and CYP3A4 may increase Terbifin's own systemic exposure. For instance, co-administration with cimetidine is documented to increase Terbifin exposure.
  • CYP Inducers: Conversely, co-administration with enzyme inducers such as rifampin is documented to decrease Terbifin systemic exposure.
  • Clearance Modification: Terbifin officially alters the clearance rate of certain substances, specifically decreasing the clearance of caffeine and increasing the clearance of cyclosporine.

Interaction-Related Constraints

The drug is formally contraindicated for use in patients with chronic or active liver disease, a condition that inherently heightens the clinical significance of any systemic interaction. Additionally, the oral granule formulation of Terbifin is required to be taken with food, a specific timing constraint related to administration.

Mechanism of Action

The mechanism of action of terbinafine is focused on two key processes that initiate fungicidal activity by initiating irreversible cell membrane disruption. It acts specifically on the fungal lipid synthesis pathway that builds the cell membrane.

Inhibition of Fungal Cell Membrane Synthesis

Terbinafine's primary biological target is the enzyme squalene epoxidase within the fungal cell. The drug non-competitively inhibits this enzyme, effectively blocking the essential ergosterol biosynthesis pathway that creates the structural component of the fungal cell membrane. This enzymatic action constitutes the primary mechanistic interaction.

Toxic Accumulation and Cell Dysregulation

Blocking the pathway causes the precursor molecule, squalene, to accumulate to toxic levels inside the fungus, while simultaneously depleting the cell of essential ergosterol. The combination of structural failure and internal toxicity results in fungal cell lysis and irreversible cellular damage.

Selectivity Against Fungal Enzymes

Terbinafine shows preferential binding for the fungal squalene epoxidase compared to the equivalent human enzyme used in cholesterol synthesis. The differential binding capacity avoids significant interference with the analogous human cholesterol synthesis pathway.

Dosage and Administration Information

Terbifin (Terbinafine Hydrochloride) is administered via two approved routes: the oral route for systemic therapy of infections like onychomycosis, and the topical route for local skin infections.

Standard Dosing and Duration

The standard adult oral dose is 250 mg once daily. This dose is prescribed for fixed durations determined by the infection site: 6 weeks for fingernail onychomycosis and typically 12 weeks for toenail onychomycosis. Full clinical effect is observed after the treatment course is completed, corresponding to the outgrowth of healthy nail tissue. For specific indications, the oral regimen for pediatric patients is weight-based, using oral granules dosed at 125 mg, 187.5 mg, or 250 mg once daily, depending on body weight.


Administration Requirements and Constraints

Oral tablets can be taken with or without food. Conversely, the oral granules must be mixed with soft, non-acidic food and swallowed immediately. The fungal diagnosis must be confirmed by laboratory analysis prior to initiating the systemic course. A missed tablet dose should be taken as soon as remembered; however, if it is within four hours of the next scheduled dose, the missed dose is skipped.

While no general dosage adjustment is required for older adults, the use of oral Terbifin is explicitly not recommended for patients with chronic or active liver disease or in individuals with moderate to severe renal impairment (creatinine clearance le 50 mL/min).

Recent Clinical Evidence

Terbifin: Recent Clinical Evidence

Evidence for Use in Onychomycosis (Fungal Nail Infection)

The research for onychomycosis has been conducted over an extended period, primarily through Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These high-level studies were designed to examine the medicine in research settings, often by comparing it to other systemic antifungal treatments. Researchers studied adult populations, including specific groups such as older adults and those with co-existing conditions like diabetes. The main goals were to monitor mycological cure—defined by laboratory test results for fungal presence—and clinical cure, which tracked the changes in the nail's appearance. Follow-up periods often lasted nearly one year, required due to the slow rate of nail regrowth. Long-term outcomes for recurrence rates extending beyond one or two years are not fully established.


Evidence for Tinea Infections (Ringworm and Athlete's Foot)

The research base for Tinea infections includes a large number of Randomized Controlled Trials evaluating both topical and oral formulations against placebo and other treatments. These studies focused on adults and adolescents, and outcomes related to physical discomfort were studied, with researchers monitoring mycological cure and clinical status based on observable signs like scaling and redness. For Tinea capitis (scalp fungus), the core research primarily involves RCTs focused on prepubescent children. Research exploring short-term changes provides insight into the initial symptom patterns, with follow-up durations typically limited to 4 to 8 weeks for skin infections.


Research Gaps and Limitations

The evidence, while extensive, highlights what is known and what is still uncertain. One key area of limited information is the long-term outcomes for the prevention of recurrence, particularly for Tinea infections of the foot. Furthermore, the measurement of clinical status (visible outcomes) used different assessment scales across studies, which may lead to variability in reported findings. Results apply only to the specific populations studied, and data for certain groups (like children under two) remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Terbifin (FAQ)

Q: Does Terbifin interact with common pain relievers like ibuprofen?

A: Official guidance, such as that provided by UK health authorities, indicates that systemic Terbifin tablets are generally safe to take with common, non-prescription pain relievers, including ibuprofen.

Q: Are there any foods or drinks that should be avoided when taking Terbifin?

A: Official documentation does not typically specify common foods that must be avoided when taking the tablets. However, given the potential for the medicine to affect liver function, official guidance often advises caution regarding alcohol consumption during systemic treatment.

Q: Does Terbifin interact with antidepressants or anxiety medications?

A: Regulatory information notes that Terbifin is described as a strong inhibitor of the enzyme CYP2D6, which is involved in breaking down many medications. This effect may increase the systemic exposure of certain co-administered drugs, including some types of antidepressants.

Q: Can people with diabetes safely use Terbifin?

A: Studies have examined the use of Terbifin in patient populations with co-existing conditions, such as diabetes. Official documents do not list diabetes as a reason not to use the medicine (a contraindication).

Q: How does Terbifin's safety profile compare across different age groups?

A: Official documentation indicates that elderly patients do not typically require a different dosage or have a side effects profile that is different from that of younger adults. However, safety and efficacy have not been established in children younger than four years of age.

Q: Do people call Terbifin by any other names?

A: The active ingredient in this medication is Terbinafine hydrochloride. This ingredient is also marketed under various brand names, such as Lamisil, depending on the country and formulation.

Q: Is Terbifin available over the counter in some places?

A: Official information indicates that while the oral tablet formulation is typically available by prescription only, some topical formulations, such as the cream, gel, or spray, may be available for purchase without a prescription.

Q: Can Terbifin cause stomach upset or nausea?

A: Yes, official documents list various gastrointestinal symptoms, including nausea, diarrhea, indigestion (dyspepsia), and abdominal pain, as Very Common adverse reactions. This frequency classification indicates they are reported by many people who take the medicine.

Q: How quickly does Terbifin usually start to work?

A: For topical formulations applied to the skin, relief of symptoms is often noted within a few days. For the systemic tablet used for nail infections, the full clinical effect is not observed until the end of the full treatment course, due to the slow outgrowth of healthy nail tissue.

Q: Can Terbifin cause a metallic or strange taste in the mouth?

A: Official documentation lists taste disturbance, which may be described as a strange or metallic taste, as an Uncommon adverse reaction. This can include a partial or total loss of taste and is often temporary, though it may be prolonged after stopping treatment.

Q: Is a rash a common or serious side effect of Terbifin?

A: Official documentation classifies a general rash and urticaria (hives) as Very Common side effects. However, rare but very serious forms of skin reactions, known as Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, are also documented as potential risks.

Q: What are the signs of a serious reaction to Terbifin?

A: Signs of a serious reaction, as listed in official patient information, include symptoms of allergy (such as swelling of the face or difficulty breathing), signs of liver problems (such as persistent nausea, yellowing of the skin, or dark urine), or signs of a severe skin reaction (such as painful red areas or blistering). If these signs are observed, immediate medical attention is necessary.

Q: Is Terbifin known to cause issues with sleep?

A: Official safety information documents list changes in sleep patterns and trouble with sleeping among the reported side effects of the medication.

Q: Can Terbifin affect my ability to drive or operate machinery?

A: Official documents state that because Terbifin may cause side effects such as dizziness, light-headedness, or tiredness in some individuals, it is important to be aware of the possibility of reduced ability to drive or operate machinery.

Q: Does Terbifin have any known interactions with herbal teas or remedies?

A: Regulatory sources typically note that there is limited information or data available regarding the interactions between Terbifin and herbal remedies or complementary medicines. These products are generally not covered by the standard interaction data for prescription drugs.

Q: What does official guidance say about Terbifin and alcohol consumption?

A: Due to the potential for systemic Terbifin to affect liver function, official guidance often advises caution regarding alcohol consumption during treatment. This is particularly relevant given the medicine is contraindicated for patients with pre-existing chronic or active liver disease.

Q: Is it normal to feel tired or fatigued when taking Terbifin?

A: Official safety documents list unusual tiredness or weakness (fatigue) as reported side effects.

Q: Does Terbifin cause skin sensitivity to sunlight?

A: Official documentation notes that increased sensitivity of the skin to sunlight (photosensitivity) has been reported as a very rare adverse reaction.

Q: Can Terbifin cause changes to hair or nails?

A: Official safety information lists hair loss as a very rare adverse reaction reported during treatment. It is important to note the medicine is primarily used to treat infections affecting the nails.

Q: What is the general advice if I accidentally take too much Terbifin?

A: Official information states that symptoms of an accidental overdose may include headache, nausea, stomach pain, and dizziness. If an accidental overdose occurs, immediate medical attention is necessary.

Q: Is it described in official sources as safe to use Terbifin while breastfeeding?

A: No, official prescribing information advises that the medicine should not be used while breastfeeding because the active substance is known to be excreted in breast milk.

Q: Why is it important to complete the full course of Terbifin?

A: Regulatory patient information states that completing the full prescribed course is necessary to ensure the infection is completely eliminated. This action also helps to lessen the chance of the infection returning after treatment has finished.

Q: Can I take Terbifin if I am also taking vitamins or supplements?

A: Regulatory sources typically note that there is limited information or data available regarding the interactions between Terbifin and vitamins or dietary supplements. These products are generally not covered by the standard interaction data for prescription drugs.

Q: Do regulatory bodies list Terbifin as having a high potential for dependence?

A: Regulatory reviews indicate that the medication is not classified as a controlled substance with potential for abuse. There is no known potential for producing withdrawal effects or dependence.

Q: What is the shelf life or expiry expectation for Terbifin?

A: The shelf life and expiry expectations are specifically defined in the product labeling to ensure stability and safety. The product requires storage under controlled conditions, and unused or expired medication should be disposed of properly.

Q: What does the research say about Terbifin use in children?

A: Safety and effectiveness have not been established for children younger than four years of age. For children four years and older, systemic treatment is used for specific conditions like Tinea Capitis, and this is administered using weight-based dosing.

Q: Are there specific symptoms that mean I should stop taking Terbifin immediately?

A: Official guidance specifies that if signs of a serious reaction occur, immediate medical attention is necessary. These signs may include persistent nausea or yellowing of the skin (liver problems), difficulty breathing or swelling (allergy), or painful red areas/blistering (severe skin reaction).

How should Terbifin be stored and disposed of?

How to Store and Dispose of Terbinafine Tablets

The storage and disposal instructions for Terbinafine are strictly defined by regulatory guidelines to ensure product stability and safety.

Required Storage Conditions

Terbinafine tablets must be stored at Controlled Room Temperature, officially defined as 20^circ to 25 C (68 F to 77 F). The product must be protected from direct light and excess moisture and heat. It is mandatory to keep the medication from freezing.

Packaging and Safety

Tablets should be stored in the original container and the container must be kept tightly closed. For child safety, the medication must be stored out of the sight and reach of children.

Disposal

Unused or expired Terbinafine must be disposed of in accordance with local requirements. Patients are instructed to consult a healthcare professional regarding the proper disposal of outdated medication, ensuring compliance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terbifin found in:

A-Z Index: